# Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

> **NCT01251861** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 108 (actual)

## Conditions studied

- Recurrent Prostate Carcinoma
- Stage I Prostate Cancer AJCC v7
- Stage IIA Prostate Cancer AJCC v7
- Stage IIB Prostate Cancer AJCC v7
- Stage III Prostate Cancer AJCC v7

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Bicalutamide
- **OTHER:** Clinical Observation
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01251861
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-12-23
- **Primary completion:** 2018-07-17
- **Final completion:** 2027-03-31
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251861, "Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01251861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*